Optiver Holding
TBPH icon

Optiver Holding’s Theravance Biopharma TBPH Stock Holding History

Optiver Holding’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$952 Sell
56
-208
-79% -$3.44K ﹤0.01% 2504
2026
Q1 		$4.29K Buy
264
+38
+17% +$672 ﹤0.01% 1487
2025
Q4 		$4.23K Buy
226
+32
+16% +$531 ﹤0.01% 1483
2025
Q3 		$2.83K Buy
+194
New +$2.45K ﹤0.01% 2222

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Optiver Holding's TBPH Position: Q2 2026 in Review

Optiver Holding reduced its Theravance Biopharma (TBPH) stake by 79% in Q2 2026, selling an estimated $3.44K and leaving 56 shares worth $952. The position accounts for ﹤0.01% of the portfolio, ranked #2504.

Optiver Holding first reported a position in TBPH in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.29K in Q1 2026. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Optiver Holding held 56 shares of Theravance Biopharma worth $952 as of Q2 2026.
  • Optiver Holding sold 208 Theravance Biopharma shares in Q2 2026, an estimated $3.44K.
  • Theravance Biopharma made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2504 holding.
  • Optiver Holding first reported a position in Theravance Biopharma in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's Theravance Biopharma position peaked at $4.29K in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.